Guangxi TCM maker best known for Xiguashuang (watermelon frost) throat and mouth-ulcer remedies sold nationwide.
Guangxi TCM maker best known for Xiguashuang (watermelon frost) throat and mouth-ulcer remedies sold nationwide.
Earns mostly from a few long-established over-the-counter products, led by Watermelon Frost, sold through distributors to pharmacies, so one brand carries the company. Because these are self-medication products, demand depends on brand recognition and pharmacy shelf space, not doctors' prescriptions.
In one line: A Chinese TCM throat-lozenge maker (like a herbal Chloraseptic).
Moat: narrow (brand). Well-known heritage OTC brand for throat ailments with wide pharmacy distribution.
Headquarters: Guilin, Guangxi, China · Employees: 2,563
Size Guilin Sanjin Pharmaceutical (002275.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.05B, the 2061st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.46 on 18 Nov 2026.
Performance Over six months the shares fell 11.8%, against -12.4% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 2.6% over the last twelve months (peer median +6.3%); the operating margin is 24.4% (peer median 14.4%).
Valuation It trades at 12.8× forward earnings against a peer median of 18.4× (7th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 15.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.03B | CN¥2.03B | CN¥2.17B | CN¥2.15B | CN¥1.94B |
| Revenue growth | — | -7% | +1% | +11% | — |
| Gross profit | CN¥1.60B | CN¥1.49B | CN¥1.55B | CN¥1.51B | CN¥1.32B |
| EBITDA | n/a | CN¥616M | CN¥607M | CN¥585M | CN¥440M |
| Net income | CN¥422M | CN¥433M | CN¥522M | CN¥421M | CN¥330M |
| Free cash flow | CN¥630M | CN¥633M | CN¥515M | CN¥479M | CN¥473M |
| Capital expenditure | CN¥94.6M | CN¥123M | CN¥82.2M | CN¥76.4M | CN¥62.3M |
| Total debt | CN¥356M | CN¥514M | CN¥594M | CN¥530M | CN¥466M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guilin Sanjin Pharmaceutical 002275.SZ | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002275.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.3% | -3.7% | 6th highest of 21 |
| 6-month return | -11.8% | -12.4% | 11th highest of 21 |
| Distance from 52-week high | -35.5% | -33.5% | 10th lowest of 21 |
| Revenue growth (TTM) | -2.6% | +6.3% | 8th lowest of 21 |
| Operating margin | 24.4% | 14.4% | 7th highest of 21 |
| Forward P/E | 12.8× | 18.4× | 7th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -8.7% | 4.1% | least demanding of 17 |
| Growth delivered (Del g) | +5.5% | +14.3% | 5th lowest of 17 |
| Hurdle (Req g minus delivered) | -14.2 pp | -8.8 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +15.1 pp | +2.5 pp | 7th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.03B | -19% | -1% | 4% | 6.2× | -2.1% | +7.1% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | n/a | 0.4% | +4.8% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |